Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination With PD-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients After Failure of Frontline Therapy (ACTION)
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Nivolumab (Primary) ; TT 11 (Primary) ; Bendamustine; Fludarabine
- Indications Hodgkin's disease
- Focus Adverse reactions
- Acronyms ACTION
- Sponsors Tessa Therapeutics
- 16 Jun 2023 Results presented in the Tessa Therapeutics Media Release.
- 15 Jun 2023 Results presented in the Tessa Therapeutics Media Release.
- 15 Jun 2023 According to a Tessa Therapeutics media release, data from this study were presented at the17th International Conference on Malignant Lymphoma.